N. Bryce Robinson
A5077605772- Cardiac Valve Diseases and Treatments
- Aortic Disease and Treatment Approaches
- Infective Endocarditis Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac and Coronary Surgery Techniques
- Coronary Interventions and Diagnostics
- Aortic aneurysm repair treatments
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Cardiac Imaging and Diagnostics
- Health and Medical Research Impacts
- Acute Myocardial Infarction Research
- Infectious Aortic and Vascular Conditions
- COVID-19 and healthcare impacts
- Meta-analysis and systematic reviews
- Health Systems, Economic Evaluations, Quality of Life
- Coronary Artery Anomalies
- Atrial Fibrillation Management and Outcomes
- Congenital Heart Disease Studies
- Cardiac pacing and defibrillation studies
- Animal testing and alternatives
- Vascular Procedures and Complications
- Cardiac Health and Mental Health
- Burn Injury Management and Outcomes
Saint Francis Hospital
2022-2025
St. Francis Hospital
2018-2024
Cornell University
1982-2024
St. Francis Hospital
2006-2024
NewYork–Presbyterian Hospital
1987-2024
Weill Cornell Medicine
2019-2023
Kaiser Permanente Fontana Medical Center
2023
Arrowhead Regional Medical Center
2023
Presbyterian Hospital
2021-2022
Saint Francis Hospital
2019
Transcatheter aortic-valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis who are at increased risk for death from surgery; less known about TAVR low-risk patients.
We compared transcatheter aortic-valve replacement (TAVR), using a self-expanding bioprosthesis, with surgical in patients severe aortic stenosis and an increased risk of death during surgery.We recruited who were at as determined by the heart team each study center. Risk assessment included Society Thoracic Surgeons Predictor Mortality estimate consideration other key factors. Eligible randomly assigned 1:1 ratio to TAVR valve (TAVR group) or (surgical group). The primary end point was rate...
The risk for stroke after transcatheter aortic valve replacement (TAVR) is an important concern. Identification of predictors likely to be a critical factor aiding patient selection and management as TAVR use becomes widespread.Patients enrolled in the CoreValve US Extreme Risk High Pivotal Trials or Continued Access Study treated with self-expanding bioprosthesis were included this analysis. 1-year rate was 8.4%. Analysis hazard identified early phase (0-10 days; 4.1% strokes) late (11-365...
The coronavirus disease 2019 (COVID-19) pandemic has had an unprecedented global effect on health care.We quantified the experience and changes implemented in response to COVID-19 across cardiac surgery centers participating international research consortium.A 40-question questionnaire was e-mailed all ROMA trial (Randomized Comparison of Outcome Single Versus Multiple Arterial Grafts) 1 March 23, 2020.Participation voluntary anonymized.The assessed each center's according regional...
The frequency and clinical importance of structural valve deterioration (SVD) in patients undergoing self-expanding transcatheter aortic implantation (TAVI) or surgery is poorly understood.To evaluate the 5-year incidence, outcomes, predictors hemodynamic SVD TAVI surgery.This post hoc analysis pooled data from CoreValve US High Risk Pivotal (n = 615) SURTAVI 1484) randomized trials (RCTs); it was supplemented by Extreme trial 485) Continued Access Study 2178). Patients with severe stenosis...
Randomized controlled trials (RCT) were impacted by the COVID-19 pandemic, but no systematic analysis has evaluated overall impact of on non-COVID-19-related RCTs. The ClinicalTrials.gov database was queried in February 2020. Eligible studies included all randomized with a start date after 1 January 2010 and active during period from 2015 to 31 December effect pandemic non-COVID-19 determined piece-wise regression models using 11 March 2020 as time series (models fitted 2015-2018 data...
<h3>Importance</h3> Transcatheter aortic valve replacement (TAVR) is now a well-accepted alternative to surgical AVR (SAVR) for patients with symptomatic stenosis at increased operative risk. There interest in whether TAVR would benefit lower <h3>Objective</h3> The Society of Thoracic Surgeons Predicted Risk Mortality (STS PROM) has trended downward US trials and the STS/American College Cardiology Valve Therapy Registry. We hypothesized that if alone sufficient define decreased risk,...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue